Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
6.61
-0.02 (-0.30%)
At close: Jul 8, 2025, 4:00 PM
6.65
+0.04 (0.61%)
After-hours: Jul 8, 2025, 5:43 PM EDT
DAWN Employees
Day One Biopharmaceuticals had 181 employees as of December 31, 2024. The number of employees increased by 26 or 16.77% compared to the previous year.
Employees
181
Change (1Y)
26
Growth (1Y)
16.77%
Revenue / Employee
$894,597
Profits / Employee
-$381,657
Market Cap
670.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 181 | 26 | 16.77% |
| Dec 31, 2023 | 155 | 34 | 28.10% |
| Dec 31, 2022 | 121 | 66 | 120.00% |
| Dec 31, 2021 | 55 | 35 | 175.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DAWN News
- 4 weeks ago - Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development - GlobeNewsWire
- 4 weeks ago - Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301 - Seeking Alpha
- 2 months ago - Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Day One Reports First Quarter 2025 Financial Results and Corporate Progress - GlobeNewsWire
- 2 months ago - Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 - GlobeNewsWire
- 3 months ago - Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity - Seeking Alpha
- 4 months ago - Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress - GlobeNewsWire